Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors

Adam C. Palmer[1,2], Benjamin Izar[2,3] and Peter K. Sorger[2,*]

[1]Department of Pharmacology, Computational Medicine Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

[2]Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA

[3]Columbia University Medical Center, Columbia Center for Translational Tumor Immunology, New York, NY, USA

* Correspondence to peter_sorger@hms.harvard.edu

ACP ORCID 0000-0001-5028-7028

BI ORCID 0000-0003-2379-6702

PKS ORCID 0000-0002-3364-1838

ABSTRACT

Hundreds of clinical trials are testing whether combination therapies can increase the anti-tumor activity of Immune Checkpoint Inhibitors (ICIs). We find that the benefits of recently reported and approved combinations involving ICIs are fully accounted for by increasing the chance of a single-agent response (drug independence), with no requirement for additive or synergistic efficacy. Thus, the degree of success of combinations involving ICIs with other therapies is largely predictable.

INTRODUCTION

Immune Checkpoint Inhibitors (ICIs) have improved survival for many but not all types of cancer. To increase rates and durability of responses to ICIs, hundreds of combination clinical trials are currently underway involving a wide range of drug classes. A key hypothesis motivating these trials is that targeted drugs, cytotoxic chemotherapies and immunotherapies themselves can enhance responsiveness to ICIs through multiple mechanisms, including by increasing tumor immunogenicity[1]. As a result, the expectation is that individual patients will respond better to the combination than to monotherapy. However, as Emil Frei described in 1961[2], drug combinations can also confer clinically meaningful benefit through independent action[3,4], in which patient *populations* benefit (as measured by population-averaged outcomes, such as median progression-free-survival - PFS) even without additive or synergistic benefit to *individual* patients.

In a drug combination that improves on monotherapy via independent action, individual patients benefit primarily or entirely from whichever single drug is most active for them[3,4]. Variability among patients in the magnitude of anti-cancer drug response they experience is ubiquitous across drug classes and tumor types. With independent action, average responses across the population improve as a result of bet-hedging: administering multiple drugs increases each patient's chance of experiencing a clinically

meaningful anti-tumor response to any single drug in the combination. Additive or synergistic benefit to individual patients is only demonstrated when the activity of a combination therapy surpasses the null hypothesis of independent action as determined using single-agent data (here 'single-agent' refers to constituents that may, in some cases, also be lower order combinations). For example, we recently found that chemotherapy plus bevacizumab exhibits additivity or synergy by this definition in multiple tumor types, but many approved drug combinations for cancer provide a magnitude of benefit consistent with drug independence[3]. For the purposes of this analysis we draw no distinction between additivity or synergy, and only test whether patients' responses are superior to an inference of best single-agent response. It has recently been recognized that combinations with PD-1 and CTLA-4 inhibitors may confer benefit by increasing the chance of a clinically meaningful single-agent response (a bet-hedging strategy)[5].

METHODS

As described previously[3], we digitized PFS curves for combination therapies and their constituents. Data sources are described in Supplementary Table 1. Progression Free Survival (PFS) expected for the null hypothesis of independence was computed by randomly sampling single-agent PFS durations (with correlation $\rho=0.3\pm0.2$ to account for partial cross-resistance[3]), assigning each simulated patient the longer of the two sampled PFS values, and repeating to build a distribution of patient responses.

RESULTS

We asked whether ICI activity is enhanced in twelve recent combination therapy trials, including trials that met their primary efficacy endpoints and defined new standards of care for first-line treatment

of metastatic or advanced diseases, including melanoma, non-small cell lung cancer, small-cell lung cancer, renal cell cancer, triple-negative breast cancer, gastric cancer, and head and neck squamous cell carcinoma[6–17] (Supplementary Table 1). The analysis reported here includes an update of a previously studied cohort of melanoma patients treated with Ipilimumab plus Nivolumab[3], for which longer follow-up (42 months) is now available[6]. All but two trials exhibited PFS very close to the prediction of the independence model, and none surpassed it (Figure 1). For trials in head and neck squamous cell carcinoma, and gastric and gastroesophageal junction cancers, data on all therapies was reported for cohorts with or without enrichment for PD-L1 expression, and we found that combination therapy PFS was predictable in all cohorts. Individual patient data was digitally reconstructed[18,19] from published trial data and compared with PFS predicted from independence, to compute the Hazard Ratio attributable to additive or synergistic anti-tumor effect. Among the combination therapies examined, no clinical trial exhibited beneficial interactions (i.e. drug synergy or additivity; Figure 2), and we therefore we find no evidence that drug-enhanced immunogenicity improves ICI activity.

One example, a recent test of PD1 blockade plus RAF/MEK inhibition in BRAF-mutant melanoma, is cautionary[16]. This combination was less effective than independence would predict (Hazard Ratio=1.75, P=0.0025, n=60), perhaps because nearly all patients required dose reduction, interruption, or discontinuation due to treatment-related adverse events. Dose reductions or interruptions can compromise the efficacy of each constituent of a regimen and negate the benefit of bet-hedging. This may be of most concern when the toxicities associated with two therapies overlap, which may result in dose reduction or interruption of the more beneficial drug even if toxicities are not caused by it. In the anti-PD1 plus RAK/MEK inhibitor 'triple combination' the superior responses expected of independence reflect what should be possible by optimally stratifying patients to PD1 or RAF plus MEK

inhibition, which predicts that an effective biomarker(s) to guide choice of therapy would improve survival in BRAF-mutant melanoma compared to triple combination therapy.

The analysis described here has two primary methodological limitations. The first is that the benefit conferred by a combinations exhibiting independence varies with the correlation in response to the individual agents; we used a range that accounts for partial cross-resistance[3] on account of clinical experience that ICIs are not strongly cross-resistant with chemotherapies and other small molecule therapies. The second is that most of the trials we studied did not include a monotherapy arm for the ICI under study, requiring the use of response data from another trial testing the same ICI in comparable patient cohorts (Supplementary Table 1). A complication in this approach is that we lack information on the impact of patient demographics on drug response; in principle, more sophisticated monotherapy arms could be generated[20] (although not with public data), following approaches that FDA has accepted in regulatory review[21]. For squamous non-small cell lung cancer treated with anti-PD-1 antibody (pembrolizumab) in a combination, the best available monotherapy comparator was another anti-PD1 antibody (nivolumab)[22]. In four trials the ICI monotherapy arm involved previously-treated (rather than untreated) patients (Figure 1, arms labelled '2L'), which may underestimate ICI activity at first-line since previously-treated patients are often more resistant to therapy. The independent action model may then be unduly pessimistic, biasing the analysis in favor of concluding additivity or synergy, but not against it.

DISCUSSION

Despite the limitations inherent in a retrospective study, there is no evidence from any trial data reported to date that ICIs are synergistic or additive with other drugs. This appears to conflict with reports from pre-clinical models. Why might this arise? While it is possible the pre-clinical data are broadly misleading, we think it is more likely that in patient populations, variability in response to

individual drugs is sufficiently high that few patients receive enough benefit from both drugs for additivity or synergy to impact outcome. It should be possible to test this prediction in the future using better pre-treatment biomarkers and assays of on-treatment drug responses[23].

What are current and future implications of these findings? First, drug independence provides meaningful benefit and a sound strategy for designing new ICI combinations with predictable activity, which is desirable as the number of possible combinations grows. Current data suggests that if the predicted benefits of independence are insufficient for a new combination, it is likely to fail. Adverse effects remain the primary unknown, and better methods for predicting, preventing or mitigating toxicity are required. Second, in patients with rapidly progressing disease for whom second-line therapy may not be an option (due to declining functional status), using drugs in combination provides more chances for effective treatment upfront. In general, however, concurrent administration of independent drugs is not strictly necessary for benefit. In these cases, sequential treatments or biomarker-guided choice of treatments warrant further study. Third, better approaches to patient stratification are required to overcome the dominant role that inter-patient variability appears play in drug interaction. This will involve the development of biomarkers for all drugs in a combination, making it possible to identify patients with the opportunity to benefit from additivity or synergy. Given the difficulty of predicting response, it may be preferable to start patients on a multi-drug combination and then withdraw one or more drugs based on evidence of inactivity from on-treatment biopsies.

FUNDING: This work was funded by NCI grants U54-CA225088 to PKS and K08-CA222663 to BI.

REFERENCES

1. Heinhuis, K. M. *et al.* Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. *Ann Oncol* **30**, 219–235 (2019).
2. Frei, E. *et al.* Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate. *Blood* **18**, 431–454 (1961).
3. Palmer, A. C. & Sorger, P. K. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. *Cell* **171**, 1678-1691.e13 (2017).
4. Doroshow, J. H. & Simon, R. M. On the Design of Combination Cancer Therapy. *Cell* **171**, 1476–1478 (2017).
5. Schmidt, E. V. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. *Semin Immunopathol* **41**, 21–30 (2019).
6. Wolchok, J. D. *et al.* Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* **377**, 1345–1356 (2017).
7. Gandhi, L. *et al.* Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* **378**, 2078–2092 (2018).
8. Paz-Ares, L. *et al.* Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* **379**, 2040–2051 (2018).
9. Motzer, R. J. *et al.* Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **380**, 1103–1115 (2019).
10. Rini, B. I. *et al.* Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **380**, 1116–1127 (2019).
11. Schmid, P. *et al.* Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N. Engl. J. Med.* **379**, 2108–2121 (2018).

12. Tabernero, J. *et al.* Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. *Journal of Clinical Oncology* **37**, LBA4007 (2019).
13. Horn, L. *et al.* First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N. Engl. J. Med.* **379**, 2220–2229 (2018).
14. Paz-Ares, L. *et al.* Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet* (2019) doi:10.1016/S0140-6736(19)32222-6.
15. Robert, C. *et al.* Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N. Engl. J. Med.* **364**, 2517–2526 (2011).
16. Ascierto, P. A. *et al.* Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat. Med.* **25**, 941–946 (2019).
17. Burtness, B. *et al.* Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* **394**, 1915–1928 (2019).
18. Guyot, P., Ades, A. E., Ouwens, M. J. N. M. & Welton, N. J. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res Methodol* **12**, 9 (2012).
19. Rahman, R. *et al.* Divining Responder Populations from Survival Data. *Ann. Oncol.* (2019) doi:10.1093/annonc/mdz087.
20. Dron, L., Golchi, S., Hsu, G. & Thorlund, K. Minimizing control group allocation in randomized trials using dynamic borrowing of external control data - An application to second line therapy for non-small cell lung cancer. *Contemp Clin Trials Commun* **16**, 100446 (2019).

21. Synthetic control arms are a good option for some clinical trials. *STAT* https://www.statnews.com/2019/02/05/synthetic-control-arms-clinical-trials/ (2019).
22. Brahmer, J. *et al.* Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* **373**, 123–135 (2015).
23. Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nat. Rev. Cancer* **19**, 133–150 (2019).

DISCLOSURE

PKS is a member of the SAB or Board of Directors of Merrimack Pharmaceutical, Glencoe Software, Applied Biomath and RareCyte Inc and has equity in these companies. In the last five years the Sorger lab has received research funding from Novartis and Merck. Sorger declares that none of these relationships are directly or indirectly related to the content of this manuscript.



Figure 1. Progression Free Survival for combination therapies as observed in clinical trials and as predicted from independent activity of the therapies comprising the combination. Progression Free Survival (PFS) observed for each combination therapy (blue) was compared to that expected from the PFS distributions of the constituents of the combination (green and magenta) under the null hypothesis that each patient's PFS is the best of their two possible responses to constituent therapies (black line and grey range, which reflects uncertainty in response correlation ($\rho = 0.3 \pm 0.2$) or cross-resistance; method in [3]). 2L and 2L+ indicate data from patients treated at second-line or later; all other data are from patients previously untreated for metastatic or advanced cancer. Data sources and limitations are

described in Supplementary Table 1; limitations, where present, strengthen the evidence against additivity/synergy unless therapies are more effective at second-line than at first-line. TPS: PD-L1 Tumor Proportion Score; CPS: PD-L1 Combined Proportion Score.



Figure 2. Trials combining Immune Checkpoint Inhibitors with other cancer therapies are consistent with, or inferior to, independent drug action. Patient events (progression or censoring) from clinical trials were compared to the prediction of independent drug action by computing the Hazard Ratio (Cox Proportional Hazards model). Error bars are 95% confidence intervals. Superiority to independence would indicate 'drug additivity or synergy', while inferiority could occur for multiple reasons including antagonistic interaction, toxicity necessitating dose reduction/interruption, or strong cross-resistance. HNSCC, Head and Neck Squamous Cell Carcinoma; (N)SCLC, (Non) Small Cell Lung Cancer.

SUPPLEMENTARY TABLE 1

Indication	Treatment	Dosing	Data source	Cohort analyzed	N	Stage of treatment	Cross-trial comparison?	Notes
Metastatic Melanoma	Ipilimumab	3 mg/kg every 3 weeks for 4 doses	Wolchok et al (2017) N Engl J Med; 377:1345-56	All patients	315	Previously untreated	No. All 3 arms are from one trial	
	Nivolumab	3 mg/kg every 2 weeks	Wolchok et al (2017) N Engl J Med; 377:1345-56	All patients	316	Previously untreated		
	Ipilimumab + Nivolumab	nivolumab 1mg/kg plus ipilimumab 3mg/kg every 3 weeks for 4 doses, followed by nivolumab 3mg/kg every 2 weeks.	Wolchok et al (2017) N Engl J Med; 377:1345-56	All patients	314	Previously untreated		
Metastatic Non-Small Cell Lung Cancer (no sensitizing EGFR or ALK alterations)	Pembrolizumab	200 mg every 3 weeks for up to 35 cycles	Reck et al (2016) N Engl J Med; 375:1823-33	All patients; all have PD-L1 Tumor Proportion Score ≥ 50%	154	Previously untreated	Yes. Chemotherapy PFS is closely aligned between Reck and Gandhi: 	Figure 1 uses chemotherapy PFS data from the union of Gandhi (2018) and Reck (2016) Analysis results are indistinguishable when using only chemotherapy data from Gandhi et al (2018), where 'Investigator's Choice' chemotherapy options are identical to those in the combination arm. Both Gandhi (2018) and Reck (2016) use the same PD-L1 staining antibody and assay (D-L1 IHC 22C3 pharmDx assay, Agilent)
	Chemotherapy (Reck 2016)	Investigator's choice of five chemotherapy regimens for 4 to 6 cycles: carboplatin plus pemetrexed, cisplatin plus pemetrexed, carboplatin plus gemcitabine, cisplatin plus gemcitabine, or carboplatin plus paclitaxel	Reck et al (2016) N Engl J Med; 375:1823-33	All patients; all have PD-L1 Tumor Proportion Score ≥ 50%	151	Previously untreated		
	Chemotherapy (Gandhi 2018)	4 cycles of investigator's choice of cisplatin (75 mg/m^2) or carboplatin (5 mg/mL/min AUC) plus pemetrexed (500 mg/m^2), every 3 weeks, followed by pemetrexed (500 mg/m^2) every 3 weeks.	Gandhi et al (2018) N Engl J Med; 378:2078	PD-L1 TPS ≥ 50% subset	70	Previously untreated		
	Pembrolizumab + Chemotherapy	200 mg pembrolizumab every 3 weeks, for up to 35 cycles, plus 4 cycles of investigator's choice chemotherapy as above	Gandhi et al (2018) N Engl J Med; 378:2078	PD-L1 TPS ≥ 50% subset	132	Previously untreated		
Metastatic Squamous Non-Small Cell Lung Cancer (no sensitizing EGFR or ALK alterations)	Nivolumab	3 mg/kg every 2 weeks	Brahmer et al (2015) N Engl J Med; 373:123-35	All patients	135	Previously treated (2L)	Yes. Pembrolizumab monotherapy was not tested in Paz-Ares (2018) The best available data on single-agent PD1 blockade in this disease is Nivolumab in previously treated patients (Brahmer 2015)	PD1 monotherapy data comes from Nivolumab tested in previously-treated patients. This introduces an important limitation in interpretation: synergy may be concluded if first-line Pembrolizumab is substantially *less* efficacious than second-line Nivolumab. Alternatively, if PD1 blockade is more effective in untreated than previously-treated patients, then the evidence against synergy is stronger.
	Chemotherapy	4 cycles of investigator's choice of cisplatin (75 mg/m^2) or carboplatin (5 mg/mL/min AUC) plus pemetrexed (500 mg/m^2), every 3 weeks, followed by pemetrexed (500 mg/m^2) every 3 weeks.	Paz-Ares et al (2018) N Engl J Med; 379:2040-51	All patients	281	Previously untreated		
	Pembrolizumab + Chemotherapy	200 mg pembrolizumab every 3 weeks, for up to 35 cycles, in the first 4 cycles also with chemotherapy as above	Paz-Ares et al (2018) N Engl J Med; 379:2040-51	All patients	278	Previously untreated		
Advanced Renal Cell Carcinoma	Avelumab	10 mg/kg every 2 weeks	Vaishampayan et al (2018) Annals of Oncology; 29 (suppl_8): viii303-viii331, mdy283.086	Previously untreated subset (1L)	62	Previously untreated	Yes. Avelumab monotherapy was tested only in a single-arm trial, so it is not possible to inspect the similarity of a treatment arm common to both Motzer et al. and Vaishampayan et al.	Head-to-head trials of Sunitinib, Sorafenib, and Axitinib, as first-line monotherapies, have not found a significant difference in PFS, though differences in toxicities motivated the use of Axitinib in this combination.
	Sunitinib	50 mg daily for 4 weeks of a 6 week cycle (with dose reductions as described in the protocol)	Motzer et al (2019) N Engl J Med;380:1103-15	All patients (which are all 1L)	444	Previously untreated		
	Avelumab + Axitinib	avelumab 10 mg/kg every 2 weeks, plus axitinib 5 mg twice daily (with dose escalations or reductions as described in the protocol)	Motzer et al (2019) N Engl J Med;380:1103-15	All patients (which are all 1L)	442	Previously untreated		
Advanced Renal Cell Carcinoma	Pembrolizumab	200 mg every 3 weeks, for up to 35 cycles.	Donskov et al (2018) Annals of Oncology; 29 (suppl_8): viii303-viii331, mdy283.080	Clear-Cell subset (ccRCC)	110	Previously untreated	Yes. Pembrolizumab monotherapy was tested only in a single-arm trial, so it is not possible to inspect the similarity of a treatment arm common to both Rini et al. and Donskov et al.	Head-to-head trials of Sunitinib, Sorafenib, and Axitinib, as first-line monotherapies, have not found a significant difference in PFS, though differences in toxicities motivated the use of Axitinib in this combination.
	Sunitinib	50 mg daily for 4 weeks of a 6 week cycle (with dose reductions as described in the protocol)	Rini et al (2019) N Engl J Med;380:1116-27	All patients (which are all ccRCC)	429	Previously untreated		
	Pembrolizumab + Axitinib	Pembrolizumab 200 mg every 3 weeks for up to 35 cycles, plus axitinib 5 mg twice daily (with dose escalations or reductions as described in the protocol)	Rini et al (2019) N Engl J Med;380:1116-27	All patients (which are all ccRCC)	432	Previously untreated		
Advanced Triple-Negative Breast Cancer	Atezolizumab	15 mg/kg, or 20 mg/kg, or 1200mg (flat dose), every 21 days	Emens et al (2018) JAMA Oncol;5(1):74-82	All patients	116	21 previously untreated (1L), 95 previously treated (2L+)	Yes. Atezolizumab monotherapy was tested only in a single-arm trial, so it is not possible to inspect the similarity of a treatment arm common to both Schmid et al. and Emens et al.	ICI monotherapy data from previously-treated patients introduces a limitation as described above for Squamous NSCLC: synergy may be concluded if Atezolizumab is *less* efficacious at first-line than second-line. If Atezolizumab is more effective at first-line, then the evidence against synergy is stronger.
	Nab-Paclitaxel	100 mg/m^2 on days 1, 8 and 15 of 28 day cycles	Schmid et al (2018) N Engl J Med;379:2108-21	All patients	451	Previously untreated		
	Atezolizumab + Nab-Paclitaxel	atezolizumab 840 mg (flat dose) every 14 days, plus nab-paclitaxel as above	Schmid et al (2018) N Engl J Med;379:2108-21	All patients	451	Previously untreated		
Advanced Gastric / GEJ Cancer (HER2-negative)	Pembrolizumab	200 mg Q3W for up to 35 cycles	Tabernero et al (2019) J Clin Oncol 37, (suppl; abstr LBA4007)	PD-L1 combined positive score (CPS) ≥ 10	92	Previously untreated	No. All 3 arms are from one trial	Figure 1 presents data from the CPS ≥ 10 cohort, in which pembrolizumab is most active. Analysis of the CPS ≥ 1 cohort is also consistent with independent drug action.
	Chemotherapy	cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/d for 5 days Q3W or capecitabine d1-14 Q3W	Tabernero et al (2019) J Clin Oncol 37, (suppl; abstr LBA4007)	PD-L1 combined positive score (CPS) ≥ 10	90	Previously untreated		
	Pembrolizumab + Chemotherapy	pembrolizumab 200 mg Q3W for up to 35 cycles, plus chemotherapy as above.	Tabernero et al (2019) J Clin Oncol 37, (suppl; abstr LBA4007)	PD-L1 combined positive score (CPS) ≥ 10	99	Previously untreated		
Metastatic Melanoma	Ipilimumab	3 mg/kg every 3 weeks for 4 cycles	Wolchok et al (2017) N Engl J Med; 377:1345-56	All patients	315	Previously untreated	Yes. As Robert et al did not evaluate Ipilimumab monotherapy, data on Ipilimumab monotherapy for 4 cycles is obtained from Wolchok et al (2017) and Ascierto et al (2017). Analysis results are near-identical when using data from either trial of Ipilimumab monotherapy. Figure 1 uses data from Wolchok et al (2017).	Results are near-identical whether using Wolchok (2017) or Ascierto (2017) for the activity of Ipilimumab monotherapy. However, neither trial is an ideal comparator. Wolchok (2017) used a lower dosage than Robert (2011). In Ascierto (2017), 56% of patients had previously treated disease. However, if 10 mg/kg Ipilimumab in untreated patients would be more efficacious, then the evidence against synergy is stronger.
	Ipilimumab	10 mg/kg every 3 weeks for 4 cycles	Ascierto et al (2017) Lancet Oncol 18;611-622	All patients	365	205 previously treated, 160 previously untreated.		
	Dacarbazine	850 mg/m^2 every 3 weeks for 7 cycles	Robert et al (2011) N Engl J Med; 364:2517-26	All patients	252	Previously untreated		
	Ipilimumab + Dacarbazine	ipilimumab 10mg/kg, plus dacarbazine 850 mg/m^2, every 3 weeks for 4 cycles, followed by dacarbazine 850 mg/m^2 for 3 more cycles.	Robert et al (2011) N Engl J Med; 364:2517-26	All patients	250	Previously untreated		
BRAF-V600 mutant Metastatic Melanoma	Pembrolizumab	2 mg/kg every 3 weeks, or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks	Hamid et al (2019) Annals of Oncology; 30:582–588	Previously untreated subset	151	Previously untreated	Yes. Dabrafenib+Trametinib PFS is closely aligned between Robert and Ascierto: 	In this cohort of patients treated with Pembrolizumab monotherapy, different dosing schedules of 2mg/kg or 10mg/kg every 3 weeks show no difference in overall survival at 3 years of follow-up. (Robert C et al, 2016, DOI: 10.1200/JCO.2016.34.15_suppl.9503 Journal of Clinical Oncology 34, no. 15_suppl (May 20, 2016) 9503
	Dabrafenib + Trametinib (Robert 2019)	dabrafenib 150 mg twice daily plus trametinib 2 mg daily	Robert et al (2019) N Engl J Med; 381:626-636	All patients (all BRAF V600E/K)	563	Previously untreated		
	Dabrafenib + Trametinib (Ascierto 2019)	dabrafenib 150 mg twice daily plus trametinib 2 mg daily	Ascierto et al (2019) Nat Med 25;941-946	All patients (all BRAF V600E/K)	60	Previously untreated		
	Dabrafenib + Trametinib + Pembrolizumab	pembrolizumab 2mg/kg every 3 weeks, plus dabrafenib 150 mg twice daily plus trametinib 2 mg once daily	Ascierto et al (2019) Nat Med 25;941-946	All patients (all BRAF V600E/K)	60	Previously untreated		
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma	Pembrolizumab	200 mg every 3 weeks for up to 24 months	Burtness et al (2019) Lancet; 394:1915-28	All patients (left panel), CPS ≥ 20 (right panel)	301 133	First-line treatment for recurrent / metastatic disease	Yes. 'Extreme' PFS is closely aligned between Burtness and Vermorken: 	Keynote-048 (Burtness, 2019) evaluated Pembrolizumab, or Pembrolizumab plus chemotherapy, versus chemotherapy plus cetuximab ('Extreme'). PFS for chemotherapy without cetuximab was obtained from Vermorken (2008), which tested chemotherapy with or without Cetuximab. The shared arm in these trials, chemotherapy plus cetuximab, exhibits consistent PFS. Because the data of Vermorken (2008) does not stratify by CPS, the same chemotherapy PFS is used for the analysis of all patients and CPS ≥ 20. The assumption that chemotherapy activity does not vary by CPS is supported by the observation in Keynote-048 that the activity of chemotherapy plus cetuximab does not vary by CPS.
	Chemotherapy	cisplatin 100 mg/m^2 or carboplatin AUC 5 mg/mL/min, plus 5-FU 1000 mg/m^2/day for 4 days, every 3 weeks for up to 6 cycles	Vermorken et al (2008) N Engl J Med; 359;1116-27	All patients	220	First-line treatment for recurrent / metastatic disease		
	Extreme (Vermorken 2008)	Cetuximab 400 mg/m^2 loading, then 250 mg/m^2 weekly, plus Chemotherapy as above.	Vermorken et al (2008) N Engl J Med; 359;1116-27	All patients	222	First-line treatment for recurrent / metastatic disease		
	Extreme (Burtness 2019)	Cetuximab 400 mg/m^2 loading, then 250 mg/m^2 weekly, plus Chemotherapy as above.	Burtness et al (2019) Lancet; 394:1915-28	All patients	300	First-line treatment for recurrent / metastatic disease		
	Pembrolizumab + Chemotherapy	Pembrolizumab 200 mg every 3 weeks for up to 24 months, plus Chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 mg/mL/min, plus 5-FU 1000 mg/m^2/day for 4 days, every 3 weeks for up to 6 cycles)	Burtness et al (2019) Lancet; 394:1915-28	All patients (left panel), CPS ≥ 20 (right panel)	281 126	First-line treatment for recurrent / metastatic disease		
Extensive-Stage Small-Cell Lung Cancer	Atezolizumab	15 mg/kg or 1200 mg every 3 weeks for 16 cycles or until loss of clinical benefit	Sequist et al (2016) Annals of Oncology, 27 (suppl_6) 1425PD, https://doi.org/10.1093/annonc/mdw389.03	All patients; first 5 were PD-L1 selected, the remainder were enrolled regardless of PD-L1.	17	Previously treated (2L+)	Yes. As Horn et al (2018) and Paz-Ares et al (2019) did not evaluate Atezolizumab or Durvalumab as monotherapies, data were obtained from phase 1 trials of these PD-L1 mAbs as monotherapies by Sequist et al (2016) and Goldman et al (2018).	Because few patients were enrolled in these phase 1 trials of PD-L1 mAb monotherapy, data from Atezolizumab and Durvalumab were combined; both as PD-L1 mAb monotherapy, and for the chemotherapy and PD-L1 mAb plus chemotherapy arms in phase 3 trials (Horn et al 2018, and Paz-Ares et al 2019). ICI monotherapy data from previously-treated patients introduces a limitation as described above for Squamous NSCLC: synergy may be concluded if PD-L1 mAbs are *less* efficacious at first-line than second-line. If PD-L1 mAbs are more effective at first-line, then the evidence against synergy is stronger.
	Durvalumab	10 mg/kg every 2 weeks for up to 12 months	Goldman et al (2018) Journal of Clinical Oncology 36, no. 15_suppl, 8518, DOI: 10.1200/JCO.2018.36.15_suppl.8518	All patients	21	Previously treated (2L+)		
	Etoposide + Platinum (Horn 2018)	carboplatin: 5 mg/mL/min AUC every 3 weeks for 4 cycles etoposide: 100 mg/m^2 on days 1 - 3 of each cycle	Horn et al (2018) N Engl J Med; 379:2220-9.	All patients	202	Previously untreated		
	Etoposide + Platinum (Paz Ares 2019)	carboplatin 5-6 mg/mL/min AUC every 3 weeks for up to 6 cycles, or cisplatin 75-80 mg/m^2; and etoposide 80-100 mg/m^2 on days 1-3 of each cycle	Paz-Ares et al (2019) Lancet [Epub October 4] https://doi.org/10.1016/S0140-6736(19)32222-6	All patients	269	Previously untreated		
	Atezolizumab + Etoposide + Platinum	atezolizumab 1200 mg, plus etoposide + platinum as above, every 3 weeks for 4 cycles. Maintenance atezolizumab continues after the induction phase.	Horn et al (2018) N Engl J Med; 379:2220-9.	All patients	201	Previously untreated		
	Durvalumab + Etoposide + Platinum	durvalumab 1500 mg, plus etoposide + platinum as above, every 3 weeks for 4 cycles. Maintenance durvalumab every 4 weeks continues after the induction phase.	Paz-Ares et al (2019) Lancet [Epub October 4] https://doi.org/10.1016/S0140-6736(19)32222-6	All patients	268	Previously untreated		